ESR1 and ductal breast carcinoma in situ: Patients with ER positive and HER2neu negative DCIS also had a lower palpability rate, 13% versus 24% (p = 0.019), and a lower rate of mass on mammography, 17% versus 30% (p = 0.013), compared with other receptor combinations.